Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-08-28
2007-08-28
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
11200794
ABSTRACT:
New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.
REFERENCES:
patent: 4319039 (1982-03-01), Albers-Schonberg
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4410629 (1983-10-01), Terahara et al.
patent: 4857522 (1989-08-01), DiPietro et al.
patent: 4857547 (1989-08-01), Hoffman et al.
patent: 5099035 (1992-03-01), Saunders et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5153124 (1992-10-01), Furuya et al.
patent: 5157025 (1992-10-01), Aberg et al.
patent: 5180589 (1993-01-01), Joshi et al.
patent: 5202029 (1993-04-01), Haytko et al.
patent: 5616595 (1997-04-01), Chu et al.
patent: 5712130 (1998-01-01), Hajko et al.
patent: 5883109 (1999-03-01), Gregg et al.
patent: 5942423 (1999-08-01), Demain et al.
patent: 6444452 (2002-09-01), Keri et al.
patent: 6682913 (2004-01-01), Jekkel et al.
patent: 6695969 (2004-02-01), Grahek et al.
patent: 6696599 (2004-02-01), Jekkel et al.
patent: 6750366 (2004-06-01), Jekkel et al.
patent: 7001919 (2006-02-01), Keri et al.
patent: 2004/0039225 (2004-02-01), Jekkel et al.
patent: 0 215 665 (1987-03-01), None
patent: 0 605 230 (1994-07-01), None
patent: 0 671 170 (1995-09-01), None
patent: WO92/16276 (1992-10-01), None
patent: WO98/37220 (1998-08-01), None
patent: WO98/45410 (1998-10-01), None
patent: WO99/10499 (1999-03-01), None
patent: WO99/42601 (1999-08-01), None
patent: WO 00/17182 (2000-03-01), None
patent: WO 0033821 (2000-06-01), None
patent: WO 00/46175 (2000-08-01), None
patent: WO 01/03647 (2001-01-01), None
patent: WO 01/10813 (2001-02-01), None
patent: WO 2002/030415 (2002-04-01), None
Budavari, et al. The Merck Index. 1989. Merck and Co., Inc., p. 1222.
T. Koga et al., “Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor”,Biochimica et Biophysica Acta, vol. 1045, No. 1, pp. 115-120, Jun. 28, 1990.
Serajuddin et al. “Relative Lipophilicities, Solubilities, and Structure-Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin”,Journal of Pharmaceutical Sciences, vol. 80, No. 9, pp. 830-834, Sep. 1991.
McMaster, Chem 2O06 Lab Manual, 1997, www.chemistry.mcmaster.ca/˜chem2o6/labmanual/expt1/exp1b-i.html, pp. 1-9.
Aronhime Judith
Arvai Edit Nagyne
Keri Vilmos
Szabo Csaba
Kenyon & Kenyon LLP
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag
Zucker Paul A.
LandOfFree
Forms of pravastatin sodium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Forms of pravastatin sodium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Forms of pravastatin sodium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3847341